Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis.

Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q35407910

about

Novel immunotherapeutic approaches to the treatment of urothelial carcinoma Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor Evolving immunotherapy strategies in urothelial cancer Female with bladder cancer: what and why is there a difference?Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma.Nonmuscle invasive bladder cancer: a primer on immunotherapy.Systemic therapy for metastatic bladder cancer in 2016 and beyond.ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.A meta-analysis of the association between CTLA-4 genetic polymorphism and susceptibility of asthma

P2860

Q26744347-CC67F0D1-F35F-4CE9-87DD-2EEEC19F6EA3 Q26771960-04EB37D2-4B9A-4E2F-9FDD-F066D49DEB39 Q26823557-04699BDF-4E62-4311-B303-EBBA81CFF886 Q28066115-13B727E2-0D8F-45C6-B41C-E6E1DC02F82C Q28076041-63AFA526-0DE4-405A-98AE-5FABCD21FF4B Q35905097-5ADEBA29-F572-44B6-917D-7A663F46646C Q36107543-7825641A-488A-441C-A116-AF6111014C73 Q36342637-41632955-BDF4-45E2-8C15-4E87AED45838 Q37094072-C24EA34F-C360-4EAD-BE41-077883300969 Q38753358-24053074-D083-49E3-8314-4CE7A0A7A971 Q39499034-E1CACE2A-EE07-4FB4-81EF-260785B9E611 Q47281580-B174C6B3-C668-4659-A3D7-15F4C4A780B5 Q55005107-4642DD1E-FC05-49A8-95E7-72374202B643 Q56891530-B60CAD27-1E7B-4E7B-B2BA-FEA594A412E0

P2860

Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q35407910

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Prognostic role of HER2 expres ...... atic review and meta-analysis.

@ast

Prognostic role of HER2 expres ...... atic review and meta-analysis.

@en

type

label

Prognostic role of HER2 expres ...... atic review and meta-analysis.

@ast

Prognostic role of HER2 expres ...... atic review and meta-analysis.

@en

prefLabel

Prognostic role of HER2 expres ...... atic review and meta-analysis.

@ast

Prognostic role of HER2 expres ...... atic review and meta-analysis.

@en

P1433

Q35407910-7717F19A-4044-4318-B0BE-653874F5CBA2

P1476

Q35407910-4BB76EFC-E074-4423-8B60-32842E939ED7

P2093

Q35407910-158E58A2-D9B1-4CAD-94F6-5ABD3286D4A1

Q35407910-3B230E85-EC99-41A0-8F65-64BC49C1A930

Q35407910-40E58C57-4E6D-4797-95BC-E915266A30F2

Q35407910-5136DF93-A413-42E9-A217-C08209668F8E

Q35407910-B6D42D48-2A3C-48D6-8825-19EA59255BDE

Q35407910-BBC685E6-5EAF-4015-AC50-73A058671B25

Q35407910-F83FBD80-C8BA-4ED1-B50A-5B362BC2FF88

P2860

Q35407910-0A566A2E-8BF3-4D50-88E9-0BF738068094

Q35407910-1032AF57-2B52-4B8A-9C36-CE828B88A43E

Q35407910-147CEC8A-D5E5-45AF-912C-830ECB3DEC69

Q35407910-14A5B721-B9E8-4877-9EBA-8F8C62ECFCF7

Q35407910-17B90AFE-2F70-47FA-B9AC-9A94DC8A3B52

Q35407910-19B9CB68-D0F4-45BD-BBB1-CC1F86FF0864

Q35407910-1F80F031-0EBA-4225-A96A-F6548367F055

Q35407910-1FC92F76-88EE-47DE-9805-A7AB91552FD1

Q35407910-28DEF54A-223D-45CF-8BD8-FF493868D4EA

Q35407910-36E41F7B-9DEB-4225-A063-2777D0B88F67

P304

Q35407910-02D6D75D-CCFA-4CDF-9005-CD431A930AAC

P31

Q35407910-3921e7c1-7015-4348-a6ce-622b7d035b80

Q35407910-8C5F78BE-82F4-4B15-A71C-37903F9DE682

P356

Q35407910-A465DE0D-197D-4DE9-8E3F-E888F1F8181B

P433

Q35407910-CA0C4CFB-8E97-418A-9AFA-5CEA537B9EDA

P478

Q35407910-3F234B2E-3E20-4F65-9D9D-314E0D9648F3

P577

Q35407910-94224C4B-5873-4E32-9491-CF68573BEE5B

P698

Q35407910-F0C1C1F3-F661-49B7-B471-1E0902C14536

P356

S11255-014-0866-Z

P1433

International Urology and Nephrology

P1476

Prognostic role of HER2 expres ...... atic review and meta-analysis.

@en

P2093

Chuanliang Xu

http://www.w3.org/2001/XMLSchema#string

Junjie Zhao

http://www.w3.org/2001/XMLSchema#string

Ruixiang Song

http://www.w3.org/2001/XMLSchema#string

Shuxiong Zeng

http://www.w3.org/2001/XMLSchema#string

Weidong Xu

http://www.w3.org/2001/XMLSchema#string

Yinghao Sun

http://www.w3.org/2001/XMLSchema#string

Zhensheng Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer statistics, 2014

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Practical methods for incorporating summary time-to-event data into meta-analysis

Comprehensive molecular characterization of urothelial bladder carcinoma

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Histologic grading of noninvasive papillary urothelial neoplasms.

Functionalized polymeric nanoparticles loaded with indocyanine green as theranostic materials for targeted molecular near infrared fluorescence imaging and photothermal destruction of ovarian cancer cells.

Bladder cancer in 2010: how far have we come?

P304

87-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11255-014-0866-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25384433

http://www.w3.org/2001/XMLSchema#string